ACLX Kacepetan wutah bathi saben saham ing taun lumaku Arcellx Therapeutics

ACLX (Arcellx Therapeutics) - tandha merek perusahaan

Amidst the fierce competition for leadership in cell therapy, the GURU.Markets terminal chart for Arcellx (ACLX) shows earnings per share growth compared to last year, where the 14.70 metric confirms the current level. This price action reflects the success of myeloma treatment trials, while the operating model relies on outsourcing CAR-T drug production to certified plants.

ACLX - Wutah bathi ing taun lumaku Arcellx, Inc. ing rentang 28.04.2023 - 09.05.2026

Rincian metrik keuangan lan pasar Arcellx (ACLX)

- nilai saham lan prakiraan konsensus rega:
Rega bursa Arcellx Inc|ACLX - Bagan rega target
- data kapitalisasi pasar:
Nilai pasar Arcellx Therapeutics|ACLX - Nilai Perusahaan
- data ekuitas miturut neraca:
Ekuitas saben Saham Arcellx|ACLX - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku arcellx.com|ACLX - Aset Agregat Perusahaan
- indikator beban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Arcellx|ACLX - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas arcellx.com|ACLX - Gunggung utang perusahaan|Utang-utang marang nilai buku Arcellx Therapeutics|ACLX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Arcellx|Likuiditas cepet arcellx.com
- statistik bathi lan rasio pasar:
ACLX - Penghasilan resik|Prakiraan bathi resik Arcellx|ACLX - Pangali P/E|Pangali Forward P/E Arcellx Therapeutics|ACLX - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Arcellx Therapeutics|ACLX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Arcellx|ACLX - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan arcellx.com|ACLX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Arcellx
Pambiji fundamental:ACLX Arcellx Inc
Produk sing diprodhuksi Arcellx, Inc.

This indicator tracks the percentage change in net income per share over a twelve-month period, allowing for an assessment of business scaling rates prior to the publication of final reports. By analyzing the annual dynamics of net income per share, an investor can observe the capital burn rate on R&D, which is critical for Arcellx (ACLX) due to the absence of commercial sales and the high risks associated with the development of CAR-T therapy.

Pesaing utama

Kacepetan wutah bathi saben saham ing taun lumaku TG Therapeutics Inc (TGTX)|Wutah bathi saben saham ing taun lumaku Disc Medicine Corp|Kacepetan wutah bathi saben saham ing taun lumaku Syndax Corp SNDX|Wutah bathi ing taun lumaku KURA|adctherapeutics.com - Wutah bathi saben saham ing taun iki|Wutah bathi ing taun lumaku FHTX (Foghorn Therapeutics Inc.)|Wutah bathi ing taun lumaku Vor Biopharma, Inc. VOR|NKTX - Wutah bathi saben saham ing taun lumaku|Tambahing bathi saben saham ing taun lumaku COEP (Coeptis Therapeutics)|ATNM: Wutah bathi ing taun lumaku|Wutah bathi resik saben saham ing taun iki estrellabio.com|CASI (CASI Pharmaceuticals Inc.) - Wutah bathi ing taun lumaku|Kacepetan wutah bathi saben saham ing taun lumaku Marker Bio MRKR|Wutah bathi saben saham ing taun lumaku IN8bio, Inc (INAB)|Wutah bathi saben saham ing taun lumaku ERNA (eternatx.com)|Wutah bathi saben saham ing taun lumaku GT Biopharma, Inc. GTBP|Aptose Biosciences Inc - Wutah bathi saben saham ing taun lumaku|BPTH: Wutah bathi resik saben saham ing taun iki|MEIP (MEI Pharma Inc) - Wutah bathi saben saham ing taun iki|VINC: Wutah bathi ing taun lumaku